Tongjitang Chinese Medicines, a Chinese pharmaceutical company focused on modernized traditional Chinese medicine, filed for an IPO Monday. The company plans to offer 8.35 million ADSs, including 1.515 million from selling shareholders, at an expected price range of $15.00 to $17.00. Merrill Lynch and UBS are the lead underwriters on the deal.
